Stock Price Movement and Market Context
On 18 Mar 2026, Hikal Ltd’s stock recorded an intraday low of Rs.166, representing its lowest price point in the last 52 weeks. Despite this, the stock managed to gain 1.27% over the past two trading sessions, with a day’s high reaching Rs.176.55, up 3.82% intraday. The day’s trading range showed volatility, with the price swinging between Rs.166 and Rs.176.55. The stock’s day change was 1.41%, aligning closely with the Pharmaceuticals & Biotechnology sector’s overall performance.
However, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend. This technical positioning contrasts with the broader market, where the Sensex advanced by 0.84% to close at 76,711.41, supported by gains in mega-cap stocks. Notably, the Sensex itself is trading below its 50-day moving average, which in turn is below the 200-day moving average, indicating some caution in the broader market.
Long-Term Performance and Valuation Metrics
Hikal Ltd’s one-year performance has been disappointing, with the stock declining by 57.04%, significantly underperforming the Sensex’s 1.87% gain over the same period. The stock’s 52-week high was Rs.456.60, underscoring the extent of the recent decline. Over the last five years, the company’s operating profits have contracted at a compound annual growth rate (CAGR) of -16.94%, reflecting challenges in sustaining growth.
Financially, the company exhibits a high Debt to EBITDA ratio of 2.51 times, indicating a relatively elevated debt burden compared to earnings before interest, tax, depreciation, and amortisation. Return on Equity (ROE) averages 8.00%, which is modest and suggests limited profitability relative to shareholders’ funds. Additionally, the Return on Capital Employed (ROCE) for the half-year ended December 2025 was recorded at 4.44%, one of the lowest in recent periods, further highlighting subdued capital efficiency.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Profitability and Earnings Trends
Hikal Ltd’s profitability has deteriorated over the past year, with profits falling by 66.4%. This decline has contributed to the stock’s underperformance relative to the BSE500 index over one year, three years, and the last three months. The company’s flat results reported in December 2025 further underscore the lack of momentum in earnings growth.
Despite these challenges, the stock’s valuation metrics suggest some degree of attractiveness. The enterprise value to capital employed ratio stands at 1.5, indicating that the stock is trading at a discount compared to its peers’ historical averages. This valuation discount reflects market caution given the company’s recent financial performance and sector dynamics.
Shareholding and Market Sentiment
The majority of Hikal Ltd’s shares are held by promoters, which may provide some stability in ownership structure. However, the company’s Mojo Score remains low at 23.0, with a Mojo Grade of Strong Sell as of 14 Nov 2025, downgraded from Sell. This rating reflects the combination of weak fundamentals, subdued profitability, and technical indicators.
Technical Indicators Signal Continued Pressure
Technical analysis of Hikal Ltd’s stock reveals predominantly bearish signals across multiple timeframes. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly charts. The Relative Strength Index (RSI) is bearish on the weekly chart, while the monthly chart shows no clear signal. Bollinger Bands also indicate bearish trends on weekly and monthly timeframes.
Other momentum indicators such as the Know Sure Thing (KST) and Dow Theory assessments are mildly bearish, reinforcing the subdued technical outlook. The On-Balance Volume (OBV) indicator is mildly bearish on the weekly chart and shows no clear trend monthly, suggesting limited buying pressure.
Hikal Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Concerns
Hikal Ltd’s stock decline to Rs.166, its 52-week low, is underpinned by a combination of weak long-term growth, diminished profitability, and elevated leverage. The company’s operating profit contraction at a CAGR of -16.94% over five years and a high Debt to EBITDA ratio of 2.51 times highlight financial strain. The modest ROE and low ROCE further reflect limited returns on invested capital.
Technically, the stock remains under pressure with bearish signals dominating across multiple indicators and timeframes. The stock’s underperformance relative to the Sensex and BSE500 indices over various periods emphasises the challenges faced by the company within its sector.
While the valuation metrics suggest the stock is trading at a discount compared to peers, this is reflective of the market’s cautious stance given the company’s recent financial and technical profile.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
